Tae Woo Park, MD, MSc
Assistant Professor
Boston University School of Medicine
Dept of Psychiatry

MD, Case Western Reserve University

Dr. Park is an addiction psychiatrist and researcher. He is certified by the American Board of Psychiatry and Neurology in General Adult Psychiatry and Addiction Psychiatry. He attended Case Western Reserve University School of Medicine and completed a General Psychiatry residency and Addiction Psychiatry fellowship at the Western Psychiatric Institute and Clinic and the University of Pittsburgh Medical Center. After completion of his clinical fellowship, he completed the Veteran Affairs Interprofessional Advanced Fellowship in Addiction Treatment at the Boston VA Healthcare System. During his VA fellowship, Dr. Park collaborated on research studies with researchers at VA Health Services Research and Development in Boston and Ann Arbor. He also worked closely with researchers from the Clinical Addiction Research and Education Unit in the Section of General Internal Medicine at Boston University School of Medicine. After completing his research fellowship, he was an attending addiction psychiatrist at Rhode Island Hospital, an Assistant Professor of Medicine and Psychiatry and Human Behavior at Brown University, and a researcher in the Division of General Internal Medicine at Brown. During his research fellowship in Boston, Dr. Park conducted studies on mental health and addiction in primary care settings and the risks of benzodiazepine use in patients taking opioids for pain or addiction. While at Brown University, Dr. Park focused on research that assists patients in reducing benzodiazepine use in opioid maintenance treatment. He also helped develop the Brown University Addiction Medicine Fellowship, an American Board of Addiction Medicine-accredited addiction fellowship. As the Associate Program Director of the fellowship, he was involved in clinical and didactic teaching of fellows and residents. At Rhode Island Hospital, he also worked as a provider in a buprenorphine maintenance and general addiction outpatient clinic.

Distress Tolerance and Benzodiazepine Discontinuation in Opioid Agonist Therapy
08/15/2017 - 07/31/2022 (PI)

(SAMHSA) Addiction and Behavioral Health Outpatient Recovery (A.B.O.V.E)
09/30/2018 - 09/29/2021 (PI)


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Park TW, Sikov J, dellaBitta V, Saitz R, Walley AY, Drainoni ML. "It could potentially be dangerous... but nothing else has seemed to help me.": Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. J Subst Abuse Treat. 2021 Apr 30; 131:108455.View Related Profiles. PMID: 34098286
  2. Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction. 2020 05; 115(5):924-932.View Related Profiles. PMID: 31916306; PMCID: PMC7156323; DOI: 10.1111/add.14886;
  3. Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018 05 07; 13(1):15.View Related Profiles. PMID: 29730987; PMCID: PMC5937046; DOI: 10.1186/s13722-018-0116-2;
  4. Park TW. Debate: Are Benzodiazepines Appropriate Treatments for Patients with Substance Use Disorders? Yes. J Addict Med. 2017 Mar/Apr; 11(2):87-89. PMID: 28301370; DOI: 10.1097/ADM.0000000000000292;
  5. Lin LA, Hosanagar A, Park TW, Bohnert AS. Opioid Overdose: Risk Assessment and Mitigation in Outpatient Treatment. J Addict Med. 2016 Nov/Dec; 10(6):382-386. PMID: 27525469; PMCID: PMC5083151; DOI: 10.1097/ADM.0000000000000241;
  6. Park TW, Lin LA, Hosanagar A, Kogowski A, Paige K, Bohnert AS. Understanding Risk Factors for Opioid Overdose in Clinical Populations to Inform Treatment and Policy. J Addict Med. 2016 Nov/Dec; 10(6):369-381. PMID: 27525471
  7. Ramsey SE, Rounsaville D, Hoskinson R, Park TW, Ames EG, Neirinckx VD, Friedmann P. The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature. Subst Abuse. 2016; 10:65-8. PMID: 27512336; PMCID: PMC4975246; DOI: 10.4137/SART.S39067;
  8. Park TW, Saitz R, Nelson KP, Xuan Z, Liebschutz JM, Lasser KE. The association between benzodiazepine prescription and aberrant drug-related behaviors in primary care patients receiving opioids for chronic pain. Subst Abus. 2016 Oct-Dec; 37(4):516-520.View Related Profiles. PMID: 27092738; PMCID: PMC5708125; DOI: 10.1080/08897077.2016.1179242;
  9. Park TW, Cheng DM, Lloyd-Travaglini CA, Bernstein J, Palfai TP, Saitz R. Changes in health outcomes as a function of abstinence and reduction in illicit psychoactive drug use: a prospective study in primary care. Addiction. 2015 Sep; 110(9):1476-83.View Related Profiles. PMID: 26075702; PMCID: PMC4521992; DOI: 10.1111/add.13020;
  10. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015; 350:h2698.View Related Profiles. PMID: 26063215; PMCID: PMC4462713; DOI: 10.1136/bmj.h2698;
Showing 10 of 18 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 18 publications over 10 distinct years, with a maximum of 4 publications in 2014 and 2016

Contact for Mentoring:

85 E. Newton St Fuller Building
Boston MA 02118
Google Map

Park's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department